Download App

Log in to access Online Inquiry
Company Overview More
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.
CEO: Hallal, David L.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Moomoo > Quotes > ALVR AlloVir > Detailed Quotes

ALVR AlloVir

4.310-0.290-6.30%
Close 05/18 20:00 ET
4.31000.00%
Post Mkt Price 05/18 16:01 ET
High
4.630
Open
4.600
Turnover
2.68M
Low
4.180
Pre Close
4.600
Volume
617.11K
Market Cap
281.95M
P/E(TTM)
Loss
52wk High
26.410
Shares
65.42M
P/E(Static)
Loss
52wk Low
3.210
Float Cap
156.78M
Bid/Ask %
84.87%
Historical High
48.960
Shs Float
36.38M
Volume Ratio
1.13
Historical Low
3.210
Dividend TTM
--
Div Yield TTM
--
P/B
1.47
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
1.70%
Amplitude
9.78%
Avg Price
4.344
Lot Size
1
Float Cap
156.78M
Bid/Ask %
84.87%
Historical High
48.960
Shs Float
36.38M
Volume Ratio
1.13
Historical Low
3.210
Dividend TTM
--
P/B
1.47
Dividend LFY
--
Turnover Ratio
1.70%
Amplitude
9.78%
Avg Price
4.344
Lot Size
1
Price Forecast

No Data

News

Comment